Vofopitant (GR 205171)
98%
- Product Code: 109909
CAS:
168266-90-8
| Molecular Weight: | 432.44 g./mol | Molecular Formula: | C₂₁H₂₃F₃N₆O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Vofopitant is primarily used in the treatment of nausea and vomiting, particularly those induced by chemotherapy or post-operative conditions. It functions as a neurokinin-1 (NK1) receptor antagonist, effectively blocking the action of substance P, a neuropeptide involved in the vomiting reflex. This makes it a valuable component in antiemetic regimens, often combined with other medications like corticosteroids or 5-HT3 antagonists to enhance its efficacy. Its application is especially beneficial in managing acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV), improving patient comfort and quality of life during cancer treatment. Additionally, it has been explored for potential use in other conditions where substance P plays a role, such as migraine and anxiety disorders, though these applications are still under investigation.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $2,576.21 |
+
-
|
Vofopitant (GR 205171)
Vofopitant is primarily used in the treatment of nausea and vomiting, particularly those induced by chemotherapy or post-operative conditions. It functions as a neurokinin-1 (NK1) receptor antagonist, effectively blocking the action of substance P, a neuropeptide involved in the vomiting reflex. This makes it a valuable component in antiemetic regimens, often combined with other medications like corticosteroids or 5-HT3 antagonists to enhance its efficacy. Its application is especially beneficial in managing acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV), improving patient comfort and quality of life during cancer treatment. Additionally, it has been explored for potential use in other conditions where substance P plays a role, such as migraine and anxiety disorders, though these applications are still under investigation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :